Journal of Oncology Pharmacy Practice最新文献

{"title":"Retrospective cross-sectional study of drug utilisation and expenditure of anticancer drugs at zonal referral hospital central, Tanzania.","authors":"Kauke Bakari Zimbwe, Yusto Julius Yona, Alphonce Bilola Chandika, Humphrey Sawira Kiwelu, Mkapa Faustine Madebele, Charity Alphonce Chiwambo","doi":"10.1177/10781552251339126","DOIUrl":"https://doi.org/10.1177/10781552251339126","url":null,"abstract":"<p><p>BackgroundEnsuring the widespread availability and accessibility of anticancer medications is crucial. This aligns with the World Health Organization's recommendation to achieve a coverage of over 80%.ObjectiveThis study aimed to analyse anticancer procurement data to identify utilisation patterns and expenditures, aiding future planning and investment in oncology pharmacy services. The findings can enhance resource allocation, ensuring better availability and accessibility for patient care.MethodologyThe retrospective cross-sectional descriptive study meticulously examined procurement, prescribing, and dispensing records at Benjamin Mkapa Hospital (BMH).ResultsThe expenses linked to anticancer medications have markedly escalated, experiencing successive increases of 5.74%, 16.12%, 24.10%, and 17.73% in 2020, 2021, 2022, and 2023, respectively. Notably, Bevacizumab, Rituximab, Trastuzumab, Docetaxel, Paclitaxel and Goserelin (3.6 mcg) were the most frequently utilised anticancer medications, accounting for over 64% of total drug dispensation from 2020 to 2023. Concurrently, the availability of essential anticancer treatments significantly improved, rising from 54% in 2020 to 84% in 2022 and 2023. Over the four-year period (2020-2023), anticancer drugs comprised a mere 2.8% (580 out of 20,542) of all prescriptions, predominantly for patients aged 46 and above, with 85% covered by health insurance. Breast, prostate, and stomach cancers stood out as the most prevalent, representing over 40%, 30%, and 5% of all reported cases, respectively.ConclusionThe oncology pharmacy department at BMH improved anticancer drug availability from 54% to 84% over four years, primarily treating breast, prostate, and stomach cancers with Taxane and ACT regimens.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251339126"},"PeriodicalIF":1.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug adverse events associated with temozolomide administration: A real-world pharmacovigilance study using the FAERS database from 2014 to 2024.","authors":"Wenpei Chen, Deji Wu, Xianjun Chen","doi":"10.1177/10781552251350618","DOIUrl":"https://doi.org/10.1177/10781552251350618","url":null,"abstract":"<p><p>BackgroundTemozolomide, an alkylating agent with antitumor effects, is commonly used to treat newly diagnosed glioblastoma multiforme (GBM) and recurrent or progressive GBM or anaplastic astrocytoma. As its usage has increased, so have reports of associated adverse events (AEs), though these AEs have not been systematically documented. Pharmacovigilance plays a key role in assessing the benefits and risks of drugs.ObjectiveTo systematically identify AEs associated with temozolomide through analysis of data from the FDA Adverse Event Reporting System (FAERS) in real-world settings.ResultsA total of 11,400 reports identified temozolomide as the primary suspect drug, leading to the identification of 200 AE signals. These AEs were linked to 27 system organ classes (SOCs), with the top five being general disorders and administration site conditions (n = 5151, ROR = 1.18), injuries, poisonings, and procedural complications (n = 2825, ROR = 0.98), blood and lymphatic system disorders (n = 2375, ROR = 6.32), gastrointestinal disorders (n = 2254, ROR = 1.08), and nervous system disorders (n = 2084, ROR = 1.05). New suspected AEs, such as mutagenic effects, aspergillosis, and intracranial hemorrhage, were identified, which were not listed in the drug's package insert. The majority of AEs (n = 758) occurred within the first month of use, though some were reported up to a year after treatment (n = 126).ConclusionsThese findings provide valuable insights for optimizing temozolomide use and minimizing its potential side effects, enhancing its safety in clinical practice.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251350618"},"PeriodicalIF":1.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.","authors":"Shirin Abadi, Andrew Pool, Anna Tinker, Ying Wang, Andrea Crameri, Dennis Jang","doi":"10.1177/10781552251351324","DOIUrl":"https://doi.org/10.1177/10781552251351324","url":null,"abstract":"<p><p>IntroductionPatients with cancer are at risk for experiencing adverse health outcomes, including drug therapy problems (DTPs). Multidisciplinary approaches to team-based care (TBC) are important in improving patient health outcomes and patient safety, while reducing redundancy and increasing efficiency.ObjectivesThe primary objective was to design and test a care model that integrated a residency-trained pharmacist into an interprofessional team, including medical oncologists and nurses, in order to optimize TBC and provision of patient-centred care. Secondary objectives were to determine the numbers and types of clinical pharmacy key performance indicators (cpKPIs) and DTPs identified and resolved pre- and post-TBC pharmacist implementation in ambulatory gynecological and lung cancer clinics.MethodsThis was a prospective, non-randomized, non-blinded study, focused on implementing a collaborative TBC model in ambulatory oncology clinics, which treated patients with gynecological or lung cancers. Applicable evidence-based literature and local expertise were used to inform the processes for engaging team members and determining evaluative metrics, which highlight successes and opportunities for improvement.ResultsA residency-trained pharmacist was successfully integrated into the existing multidisciplinary ambulatory oncology team, focused on treating patients with gynecological and lung cancers. One hundred and sixty-five clinically important cpKPIs and DTPs were identified post-TBC pharmacist implementation, as compared to thirty-two interventions at baseline. The most common documented cpKPI and DTP were medication reconciliation and drug interactions, respectively.ConclusionA collaborative, multidisciplinary TBC environment works well for delivering cancer care. The addition of a pharmacist to TBC assists with identifying and resolving clinically important cpKPIs and DTPs.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251351324"},"PeriodicalIF":1.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating patients on immune checkpoint inhibitors for cardiac adverse events: The EPICC study.","authors":"Kong Vang, Jennifer Panich, Connie Folz, Hiral Patel, Nikhila Aimalla, Yuanli Lei, Thane Drier, Paige Hergenrother, Somto Nwaedozie, Chady A Leon","doi":"10.1177/10781552251349459","DOIUrl":"https://doi.org/10.1177/10781552251349459","url":null,"abstract":"<p><p>IntroductionImmune checkpoint inhibitors (CPIs) work by engaging the patient's immune system against tumor cells and have demonstrated a significant benefit in the treatment of cancers. Activation of the patient's immune system can lead to immune-related adverse events (irAEs), which can affect almost any organ system, including the cardiovascular system. Although irAEs of the cardiovascular system are rare, they (and especially myocarditis) can be associated with high morbidity and mortality. With increased utilization of CPIs, it is paramount to evaluate the incidence and risk factors of cardiotoxicity from CPIs in a real-world practice.MethodologyThis is a retrospective cohort study conducted at a rural health system. Patients who were 18 years and older and received at least one dose of CPI from October 2013 through September 2021 were identified in electronic health records. Chart review was performed for patients who had at least one abnormal troponin level and were admitted to an acute care facility from the CPI start date through 30 days after CPI discontinuation. Exploratory associations between various characteristics and CPI-induced myocarditis were assessed with Fisher exact tests. Management and outcomes of patients with suspected CPI-induced myocarditis were captured from medical chart reviews.ResultsA total of 1515 patients were given at least one dose of a CPI between October 2013 and September 2021. Of those 1515 patients, 141 patients (9.3%) had an elevated troponin value while receiving CPI therapy or within 30 days after the last dose. Four patients with on-therapy elevated troponin were found to have myocarditis, making the incidence of suspected CPI-related myocarditis in this cohort 0.26% (95% CI: 0.07-0.67%). These case patients were more likely to have a history of acute myocardial infarction (MI), ST-elevation myocardial infarction (STEMI), or non-ST-elevation myocardial infarction (NSTEMI) (P = 0.01) as compared to included patients with no suspected myocarditis.ConclusionOur study confirms the findings of previous studies, that CPI-related myocarditis is a rare adverse event; however, more research is needed to determine risk factors.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251349459"},"PeriodicalIF":1.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological management of prostate cancer-bone metastasis and recent advancements: A comprehensive review.","authors":"Muhammed Munavvir, Mohammed Asadur Rahman, Mujeeburahiman M","doi":"10.1177/10781552251350621","DOIUrl":"10.1177/10781552251350621","url":null,"abstract":"<p><p>ObjectiveThis review discusses current strategies, new advancements and clinical trials for the treatment of bone metastases.MethodWe performed a narrative review using literatures obtained from PubMed and Google Scholar using the terms such as \"Prostate cancer\", \"bone metastases\", \"treatment\". The search included articles between 2000 and 2024. For clinical trial information, we searched www.clincialtrial.gov and included trials of Prostate cancer and bone metastases.SummaryWe go through the mechanisms of action, clinical effectiveness, and limitations of current and emerging therapies, including bisphosphonates, Receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors, novel agents and Prostate-Specific Membrane Antigen (PSMA) targeted approaches. By examining recent research and ongoing clinical trials, we seek to inform the development of optimized treatment strategies and guide future research directions. The review discuss about novel agents such as Radium-223 and Lutetium-177. Lutetium-177 is emerging as a promising treatment for metastatic prostate cancer with bone involvement. These treatment options offer significant survival benefits in patients with bone-dominant metastatic prostate cancer. The review also explores combination treatments, where integrating bone-targeted therapies with systemic prostate cancer treatments holding potential for enhanced efficacy. Ongoing clinical trials investigating novel treatment options and advanced drug delivery techniques are highlighted.ConclusionThe advancements signify a promising direction in the treatment of bone metastases in prostate cancer, highlighting the need for continuous innovation to enhance patient care and outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251350621"},"PeriodicalIF":1.0,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of pharmacist in adverse drug reaction reporting: Enhancing antifungal safety and pharmacovigilance in cancer patients.","authors":"Zunaira Akbar, Muhammad Aamir, Zikria Saleem, Zakir Khan, Muhammad Rehan Khan","doi":"10.1177/10781552251340333","DOIUrl":"10.1177/10781552251340333","url":null,"abstract":"<p><p>Globally, adverse drug reactions (ADRs) are considered as a serious public health problem. Cancer patients are more prone to ADRs due to altered physiological environment and polypharmacy. This study aimed to assess the role of pharmacists in reporting adverse drug reactions in cancer patients exposed to antifungal therapy in Pakistan.A retrospective cross-sectional study was conducted to gather data on systemic antifungal ADRs reported from 1^st January 2019 to 30^th December 2023 using electronic medical record. The Naranjo Algorithm causality scale, Common Terminology Criteria for Adverse Events severity scale and the hospital pharmacovigilance center criteria for seriousness were used to characterize the included ADRs. Clinical interventions regarding ADR management were also documented. Data were entered and analyzed by using SPSS version 25.0.The observed rate of antifungal ADRs was 0.7 per 1000 admissions. Majority of ADRs occur in adult patients (69.8%) with higher incidence in male (63.5%). Amphotericin B was associated with a high incidence of ADRs (90.5%), with nephrotoxicity being the most prevalent (50.9%). Most of the ADRs were classified as probable (92.0%), grade 2 (moderate) severity (69.8%) and medically significant (58.7%). Major intervention was discontinuation of drug (30.2%) and switched to another drug in (19.0%) patients. This study highlights the importance of pharmacist led pharmacovigilance activities in cancer patients. Future studies targeting diverse population in multiple hospitals should be conducted to further explore ADRs among cancer patients.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251340333"},"PeriodicalIF":1.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a customized combined chemical and microbiological test for qualification of aseptic preparation processes.","authors":"M Gils, E Gava, C Hanze, I Roland","doi":"10.1177/10781552251350633","DOIUrl":"10.1177/10781552251350633","url":null,"abstract":"<p><p>IntroductionTo meet legal requirements, an initial and ongoing training program of production staff must be implemented. As part of their initial and periodic qualification to carry out aseptic preparations, a media fill test (MFT) simulating aseptic processes as closely as possible must be carried out. Moreover, and especially when the handled products are toxic, it is also crucial to carry out an analysis of the chemical contamination generated during the aseptic process. For this reason, the Pharmacy Production Department wanted to implement a method combining both the media fill test and the chemical contamination test (MFT/CCT), by coupling a culture medium with a fluorescent tracer. To gain independence and to reduce costs, the department wished to manufacture its own customized bags and vials of culture medium, subsequently referred to as the \"MFT kit\", needed to carry out aseptic filling tests.MethodsThe medium chosen for developing the kit was Tryptone-soy broth (TSB) while two sterile options were available for the fluorescence tracer: quinine hydrochloride and fluorescein. A list of all manipulations handled and to be submitted to the MFT/CCT was created. After aseptic compounding, the kits were quarantined for 14 days in an incubator (22.5 °C ± 2.5 °C) in order to check that the sterility was maintained.ResultsFluorescence was visually checked for both fluorescent tracers solutions after addition of TSB and no change in fluorescence (λ = 366 nm) could be detected. Fertility tests were also carried out and the results showed that the CCT quinine solution inhibited bacterial growth and therefore gave a non-compliant result. The CCT quinine solution was subsequently withdrawn from further development of the MFT/CCT protocol. The fertility test with CCT fluorescein solution was fully compliant. The MFT/CCT protocol developed was submitted to 20 pharmacy technicians in the production department. No post-incubation turbidity was observed after handling. Post-handling UV revelation revealed an average of 2.2 [1.0-4.0] areas with traces per technician. This result reflects the non-compliance of 30% of the technicians who had to repeat the training. The average number of areas with traces among those who successfully passed the test was 1.6.Discussion/ConclusionThe development of this combined MFT/CCT protocol is promising, and opens up excellent prospects for the training and (re-)qualification of operators involved in aseptic handling. The cost of producing in-house \"MFT kits\" is much lower than the cost of commercial kits, and also makes it possible to involve teams in the implementation of MFT/CCT. A stability study on the shelf life of the kits will be conducted, with the aim of manufacturing them on a larger scale and making them available at cost price for other hospitals.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251350633"},"PeriodicalIF":1.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of thalidomide for oncology-related uses approved in Brazil: An overview of systematic reviews.","authors":"Paula Lana de Miranda Drummond, Cristine de Araújo Silva, Júlia Estevão de Souza, Bárbara Alice Rocha Magno, Giovanna Marchetti Battaglia, Raissa Carolina Fonseca Candido, Cristiane Aparecida Menezes de Pádua, Bruno Gonçalves Pereira","doi":"10.1177/10781552251348931","DOIUrl":"https://doi.org/10.1177/10781552251348931","url":null,"abstract":"<p><p><b>Objective:</b> The aim of this overview was to summarize evidence of the efficacy and safety of thalidomide in the treatment of oncology-related diseases approved in Brazil, and to assess the quality of the available data. <b>Methods:</b> A literature search was performed in the Cochrane Library, PubMed, Embase, Lilacs, and SciELO databases. Studies must contain evidence of efficacy and/or safety of thalidomide use for multiple myeloma - MM, graft-versus-host disease - GVHD, and myelodysplastic syndrome - MDS. The extracted information were: authors, year, literature search, studies design, target population, studies sample, comparisons and thalidomide dose, funding, outcomes, results / pooled effect, heterogeneity, conclusion. <b>Results:</b> This overview showed the available data about efficacy and safety of thalidomide used in the treatment of oncology-related approved indications in Brazil. It also classified the methodological quality of studies according to Amstar 2 tool. Despite of the poor quality of the articles found, they supported the efficacy of thalidomide in MM treatment. The main adverse events reported were peripheral neuropathy, infections, hematological, thromboembolic, and gastrointestinal events. Evidence supported that the more drugs combined, the greater the efficacy, but there is also a greater risk of toxicity. For the indications of GVHD and MDS no systematic reviews and/or meta-analyses that met the inclusion criteria were found. <b>Conclusions:</b> The overview confirmed thalidomide's efficacy on MM. It is important to monitor and manage the occurrence of thalidomide-related adverse events. Strict control over its use must always be reinforced to maintain its safe use.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251348931"},"PeriodicalIF":1.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review.","authors":"Chris Larck, Joseph B Elmes, R Wesley Haynes, Donald C Moore","doi":"10.1177/10781552251350959","DOIUrl":"https://doi.org/10.1177/10781552251350959","url":null,"abstract":"<p><p>The treatment paradigm for advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer has advanced rapidly over the last decade. The discovery of mutations in the <i>PIK3CA</i> gene and subsequent development of targeted therapies against this gene, which is mutated in approximately 40% of all HR-positive, HER2-negative breast cancers, has revolutionized treatment. There are currently two Food and Drug Administration (FDA) approved medications for PIK3CA mutated breast cancer-alpelisib and capivasertib. Both medications are considered category 1, or preferred option, by the National Comprehensive Cancer Network (NCCN) in the second-line setting for HR-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer. The purpose of this systematic review is to compare both the efficacy and safety profiles of alpelisib and capivasertib to better inform physicians and patients. A systematic review was conducted and included studies were analyzed for efficacy and safety endpoints. Both medications provide overall survival as well as progression free survival benefits in HR-positive, HER2-negative, PIK3CA mutated breast cancer. Safety profiles between alpelisib and capivasertib were similar. Both medications caused gastrointestinal side effects including nausea, vomiting, and loss of appetite. Capivasertib had a higher incidence of hypertension and rash whereas alpelisib had a higher incidence of hyperglycemia and alopecia. Knowledge of the side effect profiles of these medications is useful to providers as individual patient-specific factors such as comorbidities, preferences, and potential for adverse events to develop are likely to guide treatment decisions as alpelisib and capivasertib have not been compared head-to-head.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251350959"},"PeriodicalIF":1.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of oncology healthcare professional providing care to older adults prescribed oral anticancer medications in the United States: A qualitative study.","authors":"Melody N Chavez, Chloe Grabowski, Lanie A Simon, Victoria K Marshall","doi":"10.1177/10781552251346688","DOIUrl":"https://doi.org/10.1177/10781552251346688","url":null,"abstract":"<p><p>IntroductionOral anticancer agents (OAAs) offer a level of convenience to receive cancer care in the home environment. However, oncology health care providers face barriers when providing patient education to ensure patient and caregiver's ability to learn and adhere to the medication regimen. The purpose of this study was to explore the perceptions of oncology health care providers who provide care to older adults, aged 65 and older, prescribed OAAs using the Information-Motivation-Behavioral Skills model as a guiding framework.MethodsA qualitative study using a phenomenological approach, utilizing a semi-structured interview guide was used to elicit oncology health care provider perceptions of providing care for older adults prescribed OAAs. Interviews were audio recorded, transcribed and coded using Atlas.ti version 9. Inductive applied thematic analysis techniques were employed to identify emergent themes.ResultsParticipants (N = 24) were mainly female and registered nurses (45.8%). The over-arching themes included 1) patient education and assessing comprehension, 2) adherence support, and 3) most challenging aspects of oral anticancer agent care.ConclusionFindings show that delivering patient education and managing ongoing surveillance of OAAs is vital for patients aged 65 and older, however standard practices for these areas have not been established and vary depending on the resource of the institutions, the type of prescribed OAAs and patient-specific differences.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251346688"},"PeriodicalIF":1.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}